Efficacy and safety of durvalumab with or without tremelimumab in the treatment of metastatic non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Ursula Medeiros Araujo de Matos, Moana Divina da Silva Santiago, Henrique Guimaraes Barbosa Coelho et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis evaluated the efficacy and safety of durvalumab with or without tremelimumab in 2726 patients with metastatic non-small cell lung cancer (NSCLC). The study found no significant overall survival benefit with the combination therapy compared to durvalumab alone (HR 0.97; 95% CI, 0.74-1.27), while immune-related adverse events were significantly higher in the tremelimumab groups.
Key findings
- No significant overall survival benefit was observed with durvalumab plus tremelimumab (HR 0.97; 95% CI, 0.74-1.27).
- Immune-related adverse events were significantly higher in the tremelimumab-containing arms.
- The analysis included three RCTs enrolling a total of 2726 patients.
Why it matters
Understanding the efficacy and safety of combination therapies in NSCLC is crucial for optimizing treatment strategies. This study highlights the need for careful consideration of potential adverse effects when selecting immunotherapy regimens.